Ohio State is in the process of revising websites and program materials to accurately reflect compliance with the law. While this work occurs, language referencing protected class status or other activities prohibited by Ohio Senate Bill 1 may still appear in some places. However, all programs and activities are being administered in compliance with federal and state law.

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

Investigators

Thomas A Mace
Reena Shakya
Jason R Pitarresi
Benjamin Swanson
Christopher W McQuinn
Shannon Loftus
Emily Nordquist
Zobeida Cruz-Monserrate
Lianbo Yu
Gregory Young
Xiaoling Zhong
Teresa A Zimmers
Michael C Ostrowski
Thomas Ludwig
Mark Bloomston
Tanios Bekaii-Saab
Gregory B Lesinski

Filters: 2018